NAVIGATOR, NCT02508532: () Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors |
|
|
| Completed | 1 | 250 | Europe, US, RoW | Avapritinib, BLU-285 | Blueprint Medicines Corporation | Gastrointestinal Stromal Tumors (GIST), Other Relapsed or Refractory Solid Tumors | 03/20 | 06/21 | | |
NCT03056599: Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma |
|
|
| Completed | 1 | 23 | US | Multiple drug microinjection, Doxorubicin, Docetaxel, Gemcitabine, Interferon gamma, Pembrolizumab, Ipilimumab, Interferon alfa-2B, Bortezomib, Aldesleukin, Trabectedin, Eribulin, Olaratumab, Atezolizumab, Durvalumab, Avelumab, Nivolumab, Larotrectinib, Entrectinib, Avapritinib, Saline, CIVO device | Presage Biosciences, Fred Hutchinson Cancer Center, University of Washington, Northwell Health, Oregon Health and Science University | Soft Tissue Sarcoma Adult | 07/21 | 09/21 | | |
NCT04908176: A Drug-drug Interaction Study of Avapritinib and Midazolam |
|
|
| Active, not recruiting | 1 | 10 | US | Avapritinib, BLU-285, midazolam | Blueprint Medicines Corporation | Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors | 03/24 | 09/25 | | |
